# Avatrombopag for Thrombocytopenia in People With Cancer

> **NCT04437953** · PHASE2 · WITHDRAWN · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Thrombocytopenia
- Cancer
- Liver Diseases

## Interventions

- **DRUG:** Avatrombopag

## Key facts

- **NCT ID:** NCT04437953
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05-27
- **Primary completion:** 2020-12-03
- **Final completion:** 2020-12-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2020-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04437953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04437953, "Avatrombopag for Thrombocytopenia in People With Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04437953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*